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by sex steroid ablation which also increases bone marrow (BM) 
and peripheral B cell nmnbers. Innnune reconstitution is severely 
retarded in adult recipients of an allogeneic BMT. These experi- 
ments aimed to establish whether sex steroid ablation influenced 
haemopoietic recovery following allogeneic bone marrow trans- 
plantation. One day prior to allogeneic BMT, mice were surgical- 
ly castrated. 14 days after BMT, bone marrow (16x106_+l.4x106) 
and thymic (55.4x106_+l.Sx106) cell nmnbers were significantly 
increased in the castrated mice compared to sham controls 
(9.5x106_+3.0x10 ~ and 25x10~--2.6x10% These remained elevated at 
day 28 (BM: 22x106-+4.0x106 vs. 14x10~'--2.2x106; thymus: 
72x106+5.gx10 ~ vs. 45x10a--2.9x106) at whicln time splenic cellular- 
ity was also increased in the castrates. Thymocyte subsets were 
increased I4 and 28 days after BMT and castration. Thymic den- 
dritic cell numbers were also increased in castrated mice 28 days 
following BMT suggesting a possible role in graft acceptance. BM 
precursors and developing B cells were significantly increased 28 
days after BMT and castration. These central increases translated 
to a significant increase in donor-derived peripheral T and B ceils 
28 days after allogeneic BMT. Every immune-enhancing strategy 
carries the risk of exacerbating the development of graft-versus- 
host disease (GVHD). Mice were castrated at the same time as 
GVHD induction in an allogeneic setting. There was no signifi- 
cant difference in GVHD incidence or severity when comparing 
castrated and sham-castrated mice. We have previously shown 
that lymphoid recovery is enhanced in allo-BMT recipients after 
IL-7 treatment. The combination of IL-7 treatment and castra- 
tion appeared to have an additive effect in the thynms 28 days 
after allogeneic BMT. These results indicate that castration and 
the resulting ablation of sex steroids enhance haemopoietic recov- 
ery following allogeneic BMT without increasing GVHD. 
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OBJECTIVE cDGA is characterized by a profound T-cell 
immune deficiency, thymic aplasia, hypoparathyroidism, con- 
genital cardiopathy and facial dysmorphism. Therapeut ic  
attempts for this condition include thymic transplant and relat- 
ed BMT, with variable outcomes. DLI allows selective T-cel] 
reconstitution i these rare patients, eliminating the need for a 
complete BMT procedure. However, studies on donor/recipi- 
ent chimerism in the various myeloid and lymphoid fractions in 
these patients are limited. We have followed the evolution of 
molecular chimerism in these cell populations, and of the T 
cell repertoire diversity, in a cDGA patient reated by DLI (4x 
106CD3+ cells/kg), without stem-cell mobilization, condition- 
ing regimen, nor GVH prophy]axis. METHOD Molecular 
chimerism analysis was done by PCR amplification of repetitive 
DNA sequences (STR) at 2 loci enabling distinction between 
donor and recipient. Chimerism was determined at the level of 
the CD3+, CD4+, CD8+, CD19+ and CD56+ populations, 
obtained by flow cytometric ell sorting. Peripheral blood 
polymorphonuclear cells were used for myeloid lineage 
chimerism analysis. T-cell repertoire diversity and clonality 
was estimated by studying T-cell  receptor gamma chain 
rearrangements within the CD3+ cell population. RESULTS 
hmnune reconstitut ion is 100% dbnor at the T-cel l  level 
(CD3+, CD4+ and CDS+) and practically absent in other line- 
ages. A net increase in donor-derived chimerism was observed 
in granulocytes following acute hepatic and medullary (pancy- 
topenia) GVH, treated with corticosteroids and cyclosporine. 
T ceil repertoire clonal diversity in relation to clinical events 
will be presented. CONCLUSION DL1 allows rapid donor 
derived T-cel l  iminunc reconstitution, protection against 
opportunistic infections despite absence of thymus, and a low 
level of donor granulopoiesis n this patient (up to 12 nmnths 
of follow-up). 
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Background: Rate of lymphocyte recovery after allogeneic 
bone marrow transplantation has been demonstrated to be 
strong predictor of post ransplant relapse in patients with acute 
myelogenous leukemia and acute lymphoblastic leukemia. 
Peripheral blood as a source of stem cells is gradually replacing 
bone marrow for allogeneic transplants as it has already done 
for autologous tem cell transplantation. It is not clear if the 
kinetics of the lymphocyte recove W after PBSCT is comparable 
to that seen with BMT. Methods and Materials: We identi- 
fied 32 adult patients who had undergone allogeneic PBSCT 
for various hematological malignancies at Mayo Clinic, 
Rochester between I984 and 200I. Sixty-four patients who 
underwent allogeneic BMT who were matched for diagnosis, 
conditioning regimen, GVHD prophylaxis, HLA match and age 
for comparison. The absolute lymphocyte count (ALC) meas- 
ured at day 21 and 30 post transplant were obtained from the 
medical records. Results: We did not find any difference in the 
rate of lymphocyte recovery following allogeneic stem cell 
transplant with the use of BM or PBSC as the source of stem 
ceils. The median M~C on day 21 for the PBSCT group was 
170 (range 0-800) and for the BMT group was 175 (range 0- 
1090); P = 0.I. For day 30, the median ALC was 365 (range 20- 
930) for the PBSCT group and 410 (range 40-1760) for the 
BMT group respectively, P - 0.1. Discussion: Use of peripher- 
al blood stem cells has been associated with a faster hematopoi- 
etic engraftment compared to BM as the source of stem cells. 
In this study we have demonstrated that the lymphocyte recov- 
ery remains unchanged irrespective of the source of the stem 
cells. Therefore, it is likely that the previously published results 
on the prognostic value of lymphocyte recovery following BMT 
can be extrapolated to the setting of PBSCT with similar cutoff 
values. 
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EBV-ASSOCIATED LYMPHOPROLIFERATIVE DISORDER DEVELOPING 
AFTER CONDITIONING WITH RABBIT ATG 
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Post bone marrow transplant Epstein-Barr virus (EBV) associ- 
ated Lyphoproliferative disorder (LPD) can be fatal in the 
ilnmuncompronfized host. The major risk factor for the develop- 
ment of EBV-LPD is ex-vivo T cell depletion, and the in-vivo 
T-cell depletion steps caused by ATG and monoclonal T cell 
antibodies. Between March 1999 and Janual T 2001 a total of 539 
patients received allogeneic and autologus bone marrow trans- 
plants at the karmanos cancer institute. During that same time 
period 3 patients median age 21 (range 1-35) received rabbit 
ATG as part of their conditioning regimen and developed EBV- 
LPD. Occurring at a median of 70 days after bone marrow trans- 
plant (range 60-90) median dose of rabbit ATG was 
5mg/kg/dose (range 2.5-10). Treatment given in the 3 cases con- 
sisted of tapering immunosuppresion a d antiviral therapy, 
donor lymphocyte infusion in one case and chemotherapy in one 
case. We obselwcd a close association with the use of rabbit ATG 
and the development of EBV-LPD. We believe that close nmni- 
toring and periodic testing for EBV when using this agent should 
be considered when ATG is used as a part of the transplant con- 
ditioning regimen. 
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